Caliway Biopharmaceuticals Co. L
6919
Ранг среди акций
#4340
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Цена акции
$2.29
Рыночная капитализация
$3.56B
Изменение (1 день)
-2.50%
Изменение (1 год)
-57.22%
Страна
TW
Торговля Caliway Biopharmaceuticals Co. L (6919)
Категория
Healthcare
История цены акций Caliway Biopharmaceuticals Co. L (6919)
Наивысшая цена закрытия: $2.44 2026-10-01
Наименьшая цена закрытия: $0.20 2022-12-01
Наименьшая цена закрытия: $0.20 2022-12-01
История цены акций Caliway Biopharmaceuticals Co. L с 2022 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -25.32% |
| 2025 | 190.26% |
| 2024 | 181.33% |
| 2023 | 210.73% |
| 2022 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $533.13 | 25.02% |
US
|
|
| $235.39 | 776.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $889.46 | 9.25% |
NL
|
|
| $289.74 | 1.80% |
BE
|
